Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT00347321
Collaborator
Institut National de la Santé Et de la Recherche Médicale, France (Other)
212
1
1
35
6.1

Study Details

Study Description

Brief Summary

This is a phase III clinical trial comparing early tracheostomy (day 4) versus prolonged endotracheal intubation in ICU patients needing prolonged ventilatory support after cardiovascular surgery.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Dilatational Percutaneous tracheostomy
Phase 3

Detailed Description

Background: Prolonged mechanical ventilation (MV> 7 days) is required in less than 10% of patients after cardiovascular surgery but it is associated with high morbidity and mortality.

Several studies conducted in critically ill patients suggested that early percutaneous tracheotomy compared with delayed tracheotomy decreases the length of ventilator dependence and improves outcome. To date, no randomized trial has tested these possible benefits in critically ill patients after cardiac surgery.

Study objectives: A randomized trial has been designed to determine whether early tracheostomy (day 4 after cardiac surgery) in patients still on MV would reduce the number of days under MV, measured by the evaluation of ventilator-free days (VFDs). Secondary objectives are the reduction of mortality, reduction of ICU and hospital length of stay. Evaluation of organ failure evolution, infectious complications, sedation needs, patient comfort and outcome at 3 months will be also considered.

Study hypothesis: The trial will be consider positive if early tracheotomy increases the number VFDs of at least 7 days (mean) evaluated on day 60 after randomisation.

Methods :

Trial : randomized, open, controlled, monocentric Inclusion criteria: see columns below Exclusion criteria: see columns below Randomization: will use a computerised system on day 4 after cardiac surgery Procedures: see columns below Recorded data: demographic characteristics, pre, per and postoperative parameters.

From randomization until ICU discharge (or day 60), a daily chart will be completed.

Judgment criteria: see columns below Sample size and statistical analysis: using Wilcoxon bilateral test with an alpha risk of 5% and a power of 80%, we calculated that 108 patients in each arm would be needed.

Statistical analyses will use standard tests to compare population of the two arms.

Study Design

Study Type:
Interventional
Actual Enrollment :
212 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Early Percutaneous Tracheostomy in Patients Undergoing Cardiovascular Surgery and Requiring Prolonged Mechanical Ventilation
Study Start Date :
Jul 1, 2006
Actual Primary Completion Date :
Mar 1, 2009
Actual Study Completion Date :
Jun 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dilatational Percutaneous tracheostomy

Dilatational Percutaneous tracheostomy

Procedure: Dilatational Percutaneous tracheostomy
Dilatational Percutaneous tracheostomy

Outcome Measures

Primary Outcome Measures

  1. Number of ventilator-free days defined as the number of days between successful weaning from MV and day 60 after study enrolment. [between successful weaning from MV and day 60 after study enrolment.]

  2. VFDs = 0 if the patient dies before 60days. [before 60 days]

  3. VFDs= (60- X) : if the patient is successfully weaned from MV within 60 days, where X is the number of days spent receiving MV [during 60 days]

  4. VFDs = 0: if the patient requires MV for 60 days or more [during 60 days and after]

  5. The trial will be considered positive if early tracheostomy increases the number VFDs of at least 7 days (mean) [at 7 days]

Secondary Outcome Measures

  1. Other outcomes will be compared between the two arms: [during the trial]

  2. Mortality rate (day 60, in-ICU, in-hospital) [during the 60 days]

  3. ICU length of stay [during the trial]

  4. Hospital length of stay [during the trial]

  5. Duration of MV in survivors [during the trial]

  6. Organ failure evolution [during the trial]

  7. Infectious complications [during the trial]

  8. Early laryngeal and tracheal complications [during the trial]

  9. Sedation needs [during the trial]

  10. Patient comfort [during the trial]

  11. Outcome on day 90 [to 90 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Are 18 years of age or older

  • Have undergone cardiovascular surgery

  • Are still on invasive mechanical ventilation on day 4 after surgery

  • Have failed the screening test or the spontaneous breathing trial

  • Have signed the informed consent (patient or legal representative)

Exclusion Criteria:
  • Age less than18

  • Pregnant woman

  • Intubation more than 48 hours before cardiovascular surgery

  • More than 5 days on mechanical ventilation after cardiac surgery

  • Artificial heart implantation

  • Concomitant neck surgery (carotid)

  • Previously tracheostomized

  • Major hemorrhagic risk

  • Persistence of platelet count less than 50.000/mm3 after platelet transfusion

  • Prothrombin time less than 30% despite coagulation factors administration

  • Clinical evidence of ongoing infection at the proposed tracheotomy site

  • Anatomical deformity of the neck making risky a tracheostomy

  • Probability of dying the day of randomization defined by SAPSII more than 80

  • Irreversible neurological lesions

  • Decision of care limitation

  • Prior inclusion in a trial with morbidity-mortality as main judgement criteria

  • Previous enrollment in this trial

  • Consent refusal

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut de Cardiologie - Chu Pitie Salpetriere Ap-Hp Paris France 75013

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Jean Louis TROUILLET, MD,, Assistance Publique - Hôpitaux de Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00347321
Other Study ID Numbers:
  • P051013
First Posted:
Jul 4, 2006
Last Update Posted:
Dec 3, 2009
Last Verified:
Mar 1, 2007

Study Results

No Results Posted as of Dec 3, 2009